Home » About Us » News » Press Release

Press Releases
New PIVKA II Antibodies - 5/29/2018




New PIVKA-II Antibodies

Biomarker for early hepatocellular carcinoma (HCC) Diagnosis




Catalog #M01344M (Capture)
Catalog #M01343M (Detection)

• Suitable for use in ELISA
• Cross reactivity:

    - Prothrombin <0.001%
    - Thrombin <0.001%
• Developed using a proprietary
  synthetic immunogen

> Click here to download our Cancer Pairs product brochure



Protein Induced by Vitamin K Absence or antagonist-II (PIVKA-II) has been shown to be a useful marker for the diagnosis of hepatocellular carcinoma (HCC), especially when combined with alpha-fetoprotein (AFP), which is the most commonly used tumor marker for HCC. Overall, assays detecting both PIVKA-II and AFP have been shown to achieve a sensitivity and specificity 94% and 98.5%, respectively.

PIVKA-II is an abnormal form of prothrombin which is a blood coagulation protein synthesized in the liver. Usually it is converted to an active form by γ-carboxylation, however in patients with HCC or those with a vitamin K deficiency, this process is impaired and PIVKA-II is formed instead of prothrombin. Overall, PIVKA-II has shown to be an effective diagnostic biomarker in predicting the treatment response and clinical outcome of curative hepatic resection, chemotherapy, targeted therapy, radiotherapy and liver transplantation.

>Click here to learn more


Meet us at our next conference!

ASM Microbe > Request a meeting
Booth:  3433 Dates:  7 - 11 June
Location:  Georgia World Congress Center, Atlanta, GA USA

Translational Research Symposium > Request a meeting
Booth:  TBC Dates:  26 July
Location:  Brisbane, QLD Australia

AACC 2018 > Request a meeting
Booth:  1080 Dates:  29 July - 2 Aug
Location:  McCormick Place, Chicago, IL USA